PharmacyCodes



Plenaxis (Praecis Pharmaceuticals) en es it fr

Plenaxis (Praecis Pharmaceuticals) Brand names, Plenaxis (Praecis Pharmaceuticals) Analogs

Plenaxis (Praecis Pharmaceuticals) Brand Names Mixture

  • No information avaliable

Plenaxis (Praecis Pharmaceuticals) Chemical_Formula

C72H95O14N14Cl

Plenaxis (Praecis Pharmaceuticals) RX_link

http://www.rxlist.com/cgi/generic3/plenaxis.htm

Plenaxis (Praecis Pharmaceuticals) fda sheet

Plenaxis (Praecis Pharmaceuticals) msds (material safety sheet)

Plenaxis (Praecis Pharmaceuticals) Synthesis Reference

No information avaliable

Plenaxis (Praecis Pharmaceuticals) Molecular Weight

1416.06

Plenaxis (Praecis Pharmaceuticals) Melting Point

No information avaliable

Plenaxis (Praecis Pharmaceuticals) H2O Solubility

No information avaliable

Plenaxis (Praecis Pharmaceuticals) State

Liquid

Plenaxis (Praecis Pharmaceuticals) LogP

No information avaliable

Plenaxis (Praecis Pharmaceuticals) Dosage Forms

Suspension (IM Injection)

Plenaxis (Praecis Pharmaceuticals) Indication

For palliative treatment of advanced prostate cancer.

Plenaxis (Praecis Pharmaceuticals) Pharmacology

Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.

Plenaxis (Praecis Pharmaceuticals) Absorption

Following IM administration of 100 mg, abarelix is absorbed slowly with a mean peak concentration of 43.4 ng/mL observed approximately 3 days after the injection.

Plenaxis (Praecis Pharmaceuticals) side effects and Toxicity

The maximum tolerated dose of abarelix has not been determined. The maximum dose used in clinical studies was 150 mg. There have been no reports of accidental overdose with abarelix.

Plenaxis (Praecis Pharmaceuticals) Patient Information

No information avaliable

Plenaxis (Praecis Pharmaceuticals) Organisms Affected

Humans and other mammals